Clinical trial of mdroxyprogesterone acetate tablets combined with cisplatin and fluorouracil injection in the treatment of endometrial carcinoma
10.13699/j.cnki.1001-6821.2017.12.010
- VernacularTitle:醋酸甲羟孕酮片联合顺铂注射液和氟尿嘧啶注射液治疗子宫内膜癌的临床研究
- Author:
Fu-Bin ZHANG
1
;
Li-Ning CUI
;
Ke-Jun XU
Author Information
1. 宁波市第一医院妇产科
- Keywords:
endometrial carcinoma;
medroxyprogesterone acetate;
cisplatin;
fluorouracil
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(12):1106-1109
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of Medroxyprogesterone acetate combined with cisplatin and fluorouracil in the treatment of endometrial carcinoma.Methods One hundred and sixty-six patients with stage Ⅰ,Ⅱ endometrial carcinoma were randomly divided into the control group and treatment group,with 83 cases in each group.Control group was given cisplatin 80 mg · m-2,intravenous drip on day 1 + fluorouracil 4500 mg · m-2,intravenous drip on day 1-4(12 times).On the basis of the control group,the treatment group was orally given medroxyprogesterone acetate tablets 3 months before chemotherapy,250 mg,qd.Serum carbohydrate antigen 125 (CA125),carbohydrate antigen 19-9 (CA19-9),human epididymis protein 4 (HE4),vascular endothelial growth factor(VEGF),matrix metalloproteinase-9 (MMP-9),efficiency of treatment and incidence of adverse reactions before and after treatment were compared between the two groups.Results After treatment,the total effective rate of the treatment group and the control group were 81.92％ (68/83) and 67.47％ (56/83),the difference was statistically significant(P ＜ 0.05).After treatment,the CA125 concentration of the treatment group and the control group were(11.24 ± 1.46),(30.47 ±3.59)U · mL-1;CA19-9 were(6.75 ±0.84),(12.67 ±1.25) kU · L-1;HF4 were(40.23 ±4.23),(58.66 ±7.22) pmol · L-1;VEGF were(241.21 ±27.34),(329.53 ±29.13) ng · L-1;MMP-9 were(1.31 ± 0.16),(3.45 ± 0.38)ng · mL-1,statistically significant differences were found in all the indicators above between the two groups (P ＜ 0.05).The adverse drug reaction of the treatment group were gastrointestinal reaction,infection,abnormal liver function and bone marrow suppression,while those of the control group were gastrointestinal reaction,infection and bone marrow suppression.The incidences of adverse drug reaction in the treatment group and the control group were 34.94％ (29/83 cases) and 26.51％ (22/83 cases) respectively,showing no significant difference between the two groups (P ＞ 0.05).Conclusion The medroxyprogesterone acetate combined with cisplatin and fluorouracil significantly reduces the levels of serum CA125,CA19-9,HE4,VEGF,MMP-9 in patients with endometrial carcinoma,indicating its ability in improving clinical efficacy as well as maintaining high safety.
